Kairos Pharma, Ltd. (KAPA)
NYSE: KAPA · Pharmaceutical Preparations · Los Angeles, CA · filing with the SEC since 2023
Income statement, as filed
In thousands of US dollars (USD), as filed; per-share figures in US dollars; share counts. The fiscal year ends in December.| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Period ending | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 |
| Report filed | Mar 31, 2026 | Apr 15, 2025 | · | · |
| Research and development | 2,135 | 414 | 82 | · |
| General and administrative | 3,437 | 1,929 | 1,632 | · |
| Total operating expenses | 5,572 | 2,343 | 1,714 | · |
| Operating income | -5,572 | -2,343 | -1,714 | · |
| Interest expense | · | 35 | 42 | · |
| Interest and investment income | 125 | · | · | · |
| Total non-operating income (expense) | 125 | -260 | -98 | · |
| Net income | -5,447 | -2,603 | -1,812 | · |
| Earnings per share, basic | -0.30 | -0.23 | -0.17 | · |
| Earnings per share, diluted | -0.30 | -0.23 | -0.17 | · |
| Weighted average shares, basic | 18,427,787 | 11,356,451 | 10,382,515 | · |
| Weighted average shares, diluted | 18,427,787 | 11,356,451 | 10,382,515 | · |
As filed with the SEC, each figure from the newest report that carries it, and linked to it. Nothing here is computed.A dot is a line not tagged for that period. r restated by the company in a later report; b a share figure put on the newest basis or filed in the wrong unit. Hover a figure for its filing and note.
What each line is, and the XBRL concept behind it
Research and development spent on inventing what it sells next
us-gaap:ResearchAndDevelopmentExpenseGeneral and administrative the cost of running the company itself
us-gaap:GeneralAndAdministrativeExpenseTotal operating expenses the running costs together
us-gaap:OperatingExpensesOperating income profit from running the business, before interest and tax
us-gaap:OperatingIncomeLossInterest expense what its borrowing cost
us-gaap:InterestExpenseNonoperatingInterest and investment income what its cash and investments earned
us-gaap:InvestmentIncomeNetTotal non-operating income (expense) everything outside the business, together
us-gaap:NonoperatingIncomeExpenseNet income the profit or loss that belongs to the company's shareholders
us-gaap:NetIncomeLossEarnings per share, basic net income per share outstanding
us-gaap:EarningsPerShareBasicEarnings per share, diluted net income per share, counting every share that could be issued
us-gaap:EarningsPerShareDilutedWeighted average shares, basic the average count of shares outstanding
us-gaap:WeightedAverageNumberOfSharesOutstandingBasicWeighted average shares, diluted the average count with every share that could be issued
us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding